Estonia creates COVID drug, but says lack of finance for trials

10:21, 22 December 2020
Estonia creates COVID drug, but says lack of finance for trials Photo: Sergey Lantyukhov/

An effective drug for coronavirus, which has successfully passed trials on animals, has been created in Estonia, said owner of the Icosagen enterprise, biomedical technologist, academician Mart Ustav.

Speaking of the drug, Ustav stated that it could suppress any COVID mutation, except for one purely theoretical one.

He added that the developers of one of the drug’s components used antibodies taken from one Tartu patient. But Icosagen cannot bring the new drug to the consumer since there is not enough money, he said.

We cannot afford the sum of 10 million euros for the second phase, that is, clinical trials, he told the Estonian broadcaster ERR.

The World Health Organization (WHO), in collaboration with the Global Alliance for Vaccines and Immunization (GAVI) and the Coalition for Epidemic Preparedness Innovations (CEPI), has developed the international COVAX system. It allows supporting the creation of production facilities and procurement. According to the program, richer countries pay for vaccine purchases, and these funds go to help other poorer states.

A health care worker in Alaska had a severe allergic reaction after getting Pfizer’s coronavirus vaccine and was hospitalized, reported earlier.